[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332661-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332661-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","risk-of-subsequent-primary-cancers-in-bladder-cancer-survivors","Risk of subsequent primary cancers in bladder cancer survivors","","The study investigates the risk of bladder cancer survivors developing or dying from 15 specific subsequent primary cancers (SPCs). Using the SEER database, 229,554 survivors were identified and incidence and mortality rates per 10,000 person-years were calculated, alongside absolute excess risk, standardized incidence ratios, and standardized mortality ratios. Among survivors, 38,207 developed SPCs and 17,546 died. Elevated risk appeared for multiple common SPCs by sex, with distinct patterns by age and time since diagnosis, supporting clinical follow-up.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/risk-of-subsequent-primary-cancers-in-bladder-cancer-survivors/332661/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/risk-of-subsequent-primary-cancers-in-bladder-cancer-survivors/332661.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How many bladder cancer survivors and subsequent primary cancer events were identified in SEER?","Question",{"text":63,"@type":64},"A total of 229,554 bladder cancer survivors were included. Among them, 38,207 developed SPCs and 17,546 died from SPCs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which SPCs showed high risk of developing and high risk of death in men and women?",{"text":68,"@type":64},"In men, development risk was high for colorectal, breast, liver, and pancreatic cancer; death risk was high for liver and pancreatic cancer. In women, high development and death risks were observed for subsets of common SPCs reported in the study.",{"name":70,"@type":61,"acceptedAnswer":71},"How did risk vary by age and time after bladder cancer diagnosis?",{"text":72,"@type":64},"Young bladder cancer survivors had elevated development risk for ureter, kidney and renal pelvis, and lung cancer. Within 1 year of diagnosis, risks of development and death were higher for ureter, kidney and renal pelvis, prostate, and cervix cancer, while prostate cancer risk was lower after 5 years.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332661,1790618834,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Clinical and Experimental Medicine (2024) 24:247 [https://doi.org/10.1007/s10238-024-01502-0](https://doi.org/10.1007/s10238-024-01502-0)  \nRisk of subsequent primary cancers in bladder cancer survivors  \nYadong Guo1,2 · Yuke Zhang1,2 · Shiyu Mao1,2 · Wentao Zhang1,2 · FuhanYang1,2 · Ruiliang Wang1,2 · Haotian Chen1,2 · Aihong Zhang3 · Xudong Yao1,2  \nReceived: 17 June 2024 / Accepted: 6 October 2024 / Published online: 26 October 2024 © The Author(s) 2024  \nAbstract  \nWe aimed to investigate the risk of bladder cancer (BCa) survivors developing or dying from 15 specific-subsequent primary cancers (SPCs) . A total of 229,554 BCa survivors were identified from the Surveillance, Epidemiology, and End Results database. Incidence and mortality per 10,000 person-years, absolute excess risk (AER) per 10,000 person-years, standardized incidence ratios, and standardized mortality ratios were calculated. Among BCa survivors, 38,207 developed SPCs and 17,546 died of SPCs. The risk of developing and dying from SPCs was significantly high for 10 and 6 of the 12 common SPCs in men, respectively, while for 6 and 5 of the 14 common SPCs in women, respectively. The SPCs with high risk of development in men were colorectal, breast, liver, and pancreatic cancer, and the ones with high risk of death were liver and pancreatic cancer. Moreover, SPCs with a high risk of development or death among young BCa survivors include ureter, kidney and renal pelvis, and lung cancer. In addition, BCa survivors within 1 year of diagnosis have a significantly higher risk of development and death from ureter, kidney and renal pelvis, prostate, and cervix cancer, but a lower risk of prostate cancer than the general population after 5 years of diagnosis. Lung cancer had a significantly high risk of development but a low risk of death. Among BCa survivors, the risk of developing or dying from few SPCs is significantly high. These findings may provide an important basis for clinical follow-up of BCa survivors.  \nKeywords Bladder cancer survivors · Subsequent primary cancers · Risk · SEER  \nIntroduction  \nBladder cancer (BCa) is the 6th most common cancer in United States, with approximately 81,180 new cases and 17,100 deaths in 2022 [1] . Number of survivors of BCa has increased over the last decade due to progress in its early  \nYadong Guo, Yuke Zhang and Shiyu Mao have equally contributed to this study.  \n* Aihong Zhang [zhangah@tongji.edu.cn](zhangah@tongji.edu.cn)  \n* Xudong Yao [yaoxudong1967@163.com](yaoxudong1967@163.com)  \n1 Department of Urology, School of Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, People’s Republic of China  \n2 Urologic Cancer Institute, Tongji University School of Medicine, 301 Yanzhong Road, Jing’an District, Shanghai 200040, China  \n3 Department of Medical Statistics, Tongji University School of Medicine, Shanghai 200092, China  \ndiagnosis, treatment modalities, and supportive care [2] . However, it is crucial to address the complications of longterm survivors and prolong survival, such as the development of subsequent primary cancers (SPCs) [3] .  \nCurrently, a few large-scale studies have comprehensively investigated the risk of cancer survivors developing SPCs [3, 4] . Therefore, the objective of this study is to quantify the risk of BCa survivors developing or dying from 15 specificSPCs, and to explore differences in these risks in terms of age at diagnosis, time after diagnosis, and calendar year, in stratified by sex.  \nMaterials and methods Database and patient selection  \nThe Surveillance, Epidemiology, and End Results (SEER)  \n18 database covers approximately 27.8% of the US population. The clinicopathological features of BCa survivors, including sex, age at diagnosis, time of diagnosis, calendar  \nyear, and follow-up status, from 2000 to 2018 were obtained.  \n15 specific-SPCs of BCa survivors, including those of lungs, prostate, ureters, kidney and renal pelvis, colorectal, small intestine,","cbCailgVeKjZza2K","https://ap.wps.com/l/cbCailgVeKjZza2K","pdf",914255,"English","# Abstract\n# Introduction\n# Materials and methods\n## Database and patient selection\n## Follow-up and identification of SPCs\n## Outcome definition\n## Statistical analysis","[{\"question\":\"How many bladder cancer survivors and subsequent primary cancer events were identified in SEER?\",\"answer\":\"A total of 229,554 bladder cancer survivors were included. Among them, 38,207 developed SPCs and 17,546 died from SPCs.\"},{\"question\":\"Which SPCs showed high risk of developing and high risk of death in men and women?\",\"answer\":\"In men, development risk was high for colorectal, breast, liver, and pancreatic cancer; death risk was high for liver and pancreatic cancer. In women, high development and death risks were observed for subsets of common SPCs reported in the study.\"},{\"question\":\"How did risk vary by age and time after bladder cancer diagnosis?\",\"answer\":\"Young bladder cancer survivors had elevated development risk for ureter, kidney and renal pelvis, and lung cancer. Within 1 year of diagnosis, risks of development and death were higher for ureter, kidney and renal pelvis, prostate, and cervix cancer, while prostate cancer risk was lower after 5 years.\"}]","Risk of subsequent primary cancers in bladder cancer survivors | PDF",1789999012,18]